losartan-potassium and pyrazolanthrone

losartan-potassium has been researched along with pyrazolanthrone* in 2 studies

Other Studies

2 other study(ies) available for losartan-potassium and pyrazolanthrone

ArticleYear
Renoprotective effect of erythropoietin via modulation of the STAT6/MAPK/NF-κB pathway in ischemia/reperfusion injury after renal transplantation.
    International journal of molecular medicine, 2018, Volume: 41, Issue:1

    Ischemia/reperfusion injury (IRI) commonly occurs in renal transplantation. Erythropoietin (EPO) exerts a protective effect in IRI. To investigate the underlying molecular mechanism, rat models of renal IRI were established and treated with EPO and/or lentivirus‑mediated EPO-siRNA, the signal transducer and activator of transcription 6 (STAT6) inhibitor AS1517499, the JNK inhibitor SP600125, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, and the nuclear factor (NF)-κB inhibitor lactacystin. Histological examination revealed that EPO protected the kidney from IRI, through decreasing the extent of tissue congestion and inflammatory cell infiltration; however, EPO siRNA did not exert the same protective effect. In addition, the EPO level was inversely associated with renal IRI. EPO downregulated the expression of interferon-γ, interleukin (IL)-4, creatinine and caspase-3, and upregulated the expression of IL-10, thymic stromal lymphopoietin, STAT6, p-JNK and p-p38, while the opposite effects were observed with the administration of EPO-siRNA and the specific respective inhibitors. Further results revealed that MAPK (p-JNK and p-p38) acted upstream of NF-κB, and that NF-κB signaling regulated the expression of caspase-1 and -3, which may be responsible for the cytotoxicity associated with IRI. Taken together, the results of the present study demonstrated that EPO exerted a protective effect in renal IRI via the STAT6/MAPK/NF-κB pathway. This protective effect of EPO may improve reperfusion tolerance in ischemic kidneys and benefit transplant recipients.

    Topics: Acetylcysteine; Animals; Anthracenes; Apoptosis; Erythropoietin; Gene Expression Regulation; Humans; Imidazoles; Interferon-gamma; Kidney; Kidney Transplantation; Lentivirus; MAP Kinase Kinase 4; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyridines; Pyrimidines; Rats; Reperfusion Injury; RNA, Small Interfering; Signal Transduction; STAT6 Transcription Factor

2018
Activation of the Jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells.
    Journal of virology, 2005, Volume: 79, Issue:20

    Members of the mitogen-activated protein kinase (MAPK) family, including Jun amino-terminal kinase (JNK) and extracellular signal-related kinase (ERK), play an important role in the proliferation of erythroid cells in response to erythropoietin (Epo). Erythroid cells infected with the Friend spleen focus-forming virus (SFFV) proliferate in the absence of Epo and show constitutive activation of Epo signal transduction pathways. We previously demonstrated that the ERK pathway was constitutively activated in Friend SFFV-infected erythroid cells, and in this study JNK is also shown to be constitutively activated. Pharmacological inhibitors of both the ERK and JNK pathways stopped the proliferation of primary erythroleukemic cells from Friend SFFV-infected mice, with little induction of apoptosis, and furthermore blocked their ability to form Epo-independent colonies. However, only the JNK inhibitor blocked the proliferation of erythroleukemia cell lines derived from these mice. The JNK inhibitor caused significant apoptosis in these cell lines as well as an increase in the fraction of cells in G(2)/M and undergoing endoreduplication. In contrast, the growth of erythroleukemia cell lines derived from Friend murine leukemia virus (MuLV)-infected mice was inhibited by both the MEK and JNK inhibitors. JNK is important for AP1 activity, and we found that JNK inhibitor treatment reduced AP1 DNA-binding activity in primary erythroleukemic splenocytes from Friend SFFV-infected mice and in erythroleukemia cell lines from Friend MuLV-infected mice but did not alter AP1 DNA binding in erythroleukemia cell lines from Friend SFFV-infected mice. These data suggest that JNK plays an important role in cell proliferation and/or the survival of erythroleukemia cells.

    Topics: Animals; Anthracenes; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Transformed; Cell Proliferation; Cell Transformation, Viral; Cells, Cultured; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Flavonoids; JNK Mitogen-Activated Protein Kinases; Leukemia, Experimental; MAP Kinase Kinase Kinases; Mice; Retroviridae Infections; Signal Transduction; Spleen Focus-Forming Viruses; Transcription Factor AP-1; Tumor Cells, Cultured; Tumor Virus Infections

2005